REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Antigen, Epitope, Or Other Immunospecific Immunoeffector (e.g., Immunospecific Vaccine, Immunospecific Stimulator Of Cell-mediated Immunity, Immunospecific Tolerogen, Immunospecific Immunosuppressor, Etc.) > Virus Or Component Thereof Virus Or Component ThereofVirus Or Component Thereof patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/02/07 - 20070178119 - West nile vaccine The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are formulated into an immunizing vaccine. The invention also provides a method ... 07/26/07 - 20070172493 - 12832, a novel human kinase-like molecule and uses thereof Novel human kinase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase-like proteins, the invention further provides isolated kinase-like fusion proteins, antigenic peptides, and anti-kinase-like antibodies. The invention also provides kinase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, ... 07/19/07 - 20070166328 - Genetic immunization against cervical carcinoma An alphavirus vector system comprising nucleic acid of a human papilloma virus origin is disclosed. A method of treating or preventing cervical cancer is also disclosed. The method includes administering the alphavirus vector system and/or a cell comprising nucleic acid derived from human papilloma virus (HPV) to a subject. The ... 07/19/07 - 20070166327 - Mammalian antigen-presenting t cells and bi-specific t cells The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to viral specific T cells that express chimeric anti-tumor receptors. These bi-specific T cell clones are a source of effector cells that persist in vivo in response ... 07/19/07 - 20070166326 - West nile vaccine The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are formulated into an immunizing vaccine. The invention also provides a method ... 07/19/07 - 20070166325 - West nile vaccine The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are formulated into an immunizing vaccine. The invention also provides a method ... 07/19/07 - 20070166324 - West nile vaccine The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are formulated into an immunizing vaccine. The invention also provides a method ... 07/19/07 - 20070166323 - Yeast-dendritic cell vaccines and uses thereof Disclosed is a vaccine that includes a dendritic cell loaded with a yeast vehicle and antigen. Also disclosed are methods of making the vaccine and using the vaccine to elicit cellular and humoral immune responses in a mammal. Additionally, a method to elicit an immune response by administration of a ... 07/12/07 - 20070160630 - Hepatitis-c virus 4, 5 and 6 The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions ... 07/12/07 - 20070160629 - Purified active hcv ns2/3 protease A method for producing a refolded, inactive form of recombinantly produced NS2/3 protease which comprises the steps of: a) purifying the protease from inclusion bodies in the presence of a chaotropic agent; and b) refolding the purified protease by contacting it with a reducing agent and lauryldiethylamine oxide (LDAO) in ... 07/12/07 - 20070160628 - Stabilized virus-like particles and epitope display systems A chimeric polypeptide is disclosed that comprises: i) a first portion that self-assembles into an organized, repetitive, supramolecular structure that contains at least about 9 subunits, covalently linked to ii) a second polypeptide portion that comprises a peptide having a length of about 15 to about 80 amino acid residues. ... 07/05/07 - 20070154491 - Edible vaccine The object of the present invention is to provide an edible vaccine which is effective for human papilloma virus (HPV) type 16 and available in large amounts inexpensively. An edible human papilloma virus vaccine obtained by culturing a transformant of an avirulent fission yeast host, wherein the transformant carries a ... 07/05/07 - 20070154490 - Sequence of reverse transcriptase gene and method of use The present invention provides an isolated polynucleotide acid comprising a polynucleotide sequence having a substantial amount of sequence identity to the entire length of the polynucleotide sequence as set forth in SEQ ID NO: 1 or its complementary strand (SEQ ID NO: 2), the sequence is derived from RT domain ... 06/21/07 - 20070141081 - Chimeric proteins that induce effects directed against viruses The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described ... 06/21/07 - 20070141080 - Treating severe acute respiratory syndrome Severe acute respiratory syndrome is treated with a natural human alpha interferon, a dsRNA or both natural human alpha interferon and a dsRNA. ... 06/21/07 - 20070141079 - Antibody production in farm animals The present invention provides means and methods for obtaining an antibody in a mammary secretion product of a farm-animal comprising administering to said animal at least two compositions, which may be the same or different, comprising an antigen to which said antibody is to be raised, the method comprising administering ... 06/21/07 - 20070141078 - Influenza vaccine The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza ... 06/07/07 - 20070128221 - Hepatitis-c virus testing New styles of hepatitis C virus (HCV), referred to as HCV-3 and HCV-4, have been identified and sequenced. Antigenic regions of HCV-2, HCV-3 and HCV-4 polypeptides have been identified. Immunoassays for HCV and antibodies thereto are described, which allow more complete screening of blood samples for HCV, and allow HCV ... 06/07/07 - 20070128220 - Materials and methods relating to fusion proteins for inducing an immune response A nucleic acid construct is provided for delivery into living cells in vivo for inducing an immune response in a patient to an antigen; the construct directing the expression of a fusion protein, said fusion protein comprising said antigen and an adjuvant sequence derived from a plant viral coat protein. ... 06/07/07 - 20070128219 - Molecular antigen arrays The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses ... 06/07/07 - 20070128218 - Diagnosis and treatment of hepatic disorders The present invention encompasses methods and compositions useful in diagnosing and treating hepatic disorders, especially those characterized by inflammation. The method comprises administration of an agent which prevents the interaction of MAdCAM with a MAdCAM binding partner or ligand. These compositions are useful in treating diseases or disorders involving α4β7/MAdCAM ... 06/07/07 - 20070128217 - Antigenic peptides of sars coronavirus and uses thereof The present invention pertains to antigenic peptides of SARS-CoV and their use in diagnostic test methods and in the treatment of condition resulting from SARS-CoV. Furthermore, this invention provides antibodies capable of specifically recognizing the peptides of the invention. The antibodies can also advantageously be used in diagnostic test methods ... 05/31/07 - 20070122432 - Compositions and methods of treating retroviral infections The present invention relates to hyaluronidase enzyme methods, vaccines and compositions for treating or preventing pathogenic infections, such as HIV, in a patient. The invention also relates to methods, vaccines and compositions for providing immunity against HIV infection in a patient comprising treating the patient with HIV virus or HIV ... 05/31/07 - 20070122431 - Reverse genetic system for rift valley fever virus and uses thereof The present invention describes a reverse genetic system for Phlebovirus such as Rift Valley fever virus. This system comprised of RNA expression plasmids and protein expression plasmids. Additionally, the present invention also discloses the modification of this system to generate a recombinant virus that expresses a non-viral foreign gene. Furthermore, ... 05/31/07 - 20070122430 - Influenza vaccine compositions and methods of use thereof Compositions of anti-influenza vaccine containing nucleic acids encoding influenza proteins NP, M1 and NS-1 and methods of inducing a protective immune response using these compositions. Also included is the enhancement of antigenic presentation or increasing immunogenicity of an influenza NP, M1 and/or NS-1 polypeptide by modifying the three dimensional structure ... 05/31/07 - 20070122429 - Designed antigens to elicit neutralizing antibodies against sterically restricted antigen and method of using same The invention relates to the production of sterically restricted antigens, antibodies useful for the recognition of sterically restricted antigens, and methods of identifying and/or using the same. The invention further relates to methods of using the sterically restricted antigens and antibodies to treat a disease or to prevent infection with ... 05/24/07 - 20070116721 - Hepatitis b virus pre-s1 derived synthetic polypeptides and uses thereof The invention relates to a group of synthetic polypeptides, derived from the pre-S 1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies. ... 05/24/07 - 20070116720 - Infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of North American PRRS virus. The invention also provides vaccines comprising genetically modified North American PRRS ... 05/24/07 - 20070116719 - Vaccine delivery The present invention provides an immunogen composition and methods for using the same for the development of immunity. In one method, the immunogen composition is administered to prepare a person for a later booster administration. This immunogen composition includes an antigen and a polyoxyalkylene block copolymer. In another method the ... 05/24/07 - 20070116718 - Fusion proteins comprising bacteriophage coat protein and asingle-chain t cell receptor The present invention relates to novel fusion proteins comprising a bacteriophage coat protein and a single-chain T cell receptor and uses of such complexes. In one aspect, the invention relates to soluble fusion protein comprising a bacteriophage coat protein covalently linked to a single-chain T cell receptor which comprises a ... 05/24/07 - 20070116717 - Influenza vaccine compositions and methods Compositions of anti-influenza vaccine containing nucleic acids encoding influenza proteins NP, M1 and NS-1 and methods of inducing an immune response using these compositions. Also included is the enhancement of antigenic presentation or increasing immunogenicity of an influenza NP, M1 and/or NS-1 polypeptide by modifying the three dimensional structure of ... 05/24/07 - 20070116716 - Sars coronavirus s proteins and uses thereof The present invention relates to the use of a matured, glycosylated Spike (S) protein of SARS Coronavirus, fragments of the S protein, methods for producing the same, their use in detecting SARS infection, and their use or the use of their corresponding antibodies to treat patients suffering from SARS. ... 05/17/07 - 20070110768 - Use of histones for the early diagnosis and/or preventive therapy of virally-infected living cells and a biochip for carrying out said diagnosis The invention relates to a biologically-active agent, in particular, for the early diagnosis and/or preventative therapy of virally-infected living cells, the efficacy of which is selective for the cell membranes of the virally-infected cells, which are modified in a characteristic manner after viral infection. The agent includes at least one ... 05/17/07 - 20070110767 - Circovirus sequences associated with piglet weight loss disease (pwd) The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a ... 05/10/07 - 20070104733 - Tissue targeted antigenic activation of the immune response to cancers The invention provides in part methods of treating cancers of a specific organ or tissue by administering an composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate ... 05/10/07 - 20070104732 - Ligand-pseudoreceptor system for generation of adenoviral vectors with altered tropism In accordance with the present invention, there is provided a modified virus ablated of its natural receptors interactions with an unmodified or non-naturally occurring cell, said modified virus comprising a non-native polypeptide, said modified virus having an altered tropism conferred by said non-native peptide, and replicating only in cells that ... 05/03/07 - 20070098741 - Vectors derived from antibodies for transferring substances into cells The present invention provides novel polypeptides which can effectively penetrate into cells thereby transporting a substance of interest into the cells. ... 05/03/07 - 20070098740 - Stabilisation of viral microparticles A micro-particulate dry powder composition comprising a viral particle can be prepared by spray-drying a mixture of the viral particle and a stabilizing carbohydrate using an outlet temperature of no more than 60° C. ... 04/26/07 - 20070092535 - Delivery of drugs to mucosal surfaces Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions. ... 04/26/07 - 20070092534 - Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines. ... 04/19/07 - 20070087016 - Interleukin-12 as an adjuvant for paramyxoviridae vaccines A method is disclosed of reducing viral replication of a virus of the paramyxoviridae family in a host, comprising administering to the host an antigen of the virus in combination with an effective adjuvant amount of interleukin-12 (IL-12). Human viruses of the paramyxoviridae family include paramyxoviruses (e.g., parainfluenza virus 1, ... 04/19/07 - 20070087015 - Multivalent dengue virus vaccine The present invention provides vaccine compositions of attenuated dengue virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against all four dengue virus serotypes by administration of attenuated dengue-1, ... 04/12/07 - 20070082011 - Recombinant proteins from filoviruses and their use Filovirus subunit protein immunogens are produced using a recombinant expression system and combined with one or more adjuvants in immunogenic formulations. The subunit proteins include GP95, GP-FL, VP40, VP24, and NP derived from Ebola Virus and Marburg Virus. Adjuvants include saponins, emulsions, alum, and dipeptidyl peptidase inhibitors. The disclosed immunogenic ... 04/05/07 - 20070077257 - Enhanced first generation adenovirus vaccines expressing condon optimized hiv1-gag, pol, nef and modifications First generation adenoviral vectors and-recombinant adenovirus-based HIV vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof are described. The adenovirus vaccines, when directly introduced into living vertebrate tissue, express the relevant proteins, inducing a cellular immune response which specifically recognizes HIV-1. ... 03/22/07 - 20070065459 - Pharmaceutical compositions for treating papillomavirus tumors and infection A pharmaceutical composition for treating or preventing a papillomavirus infection or tumour, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined-with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region of ... 03/22/07 - 20070065458 - Vaccine compositions comprising streptococcus pneumoniae polypeptides having selected structural motifs A vaccine composition is disclosed that comprises polypeptides and fragments of polypeptides containing histidine triad residues or coiled-coil regions, some of which polypeptides or fragments lie between 80 and 680 residues in length. Also disclosed are processes for preventing infection caused by S. pneumoniae comprising administering of vaccine compositions. ... 03/22/07 - 20070065457 - Circovirus sequences associated with piglet weight loss disease (pwd) The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a ... 03/15/07 - 20070059325 - Circovirus sequences associated with piglet weight loss disease (pwd) The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a ... 03/15/07 - 20070059324 - Circovirus sequences associated with piglet weight loss disease (pwd) The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a ... 03/08/07 - 20070053934 - Polyvalent multimeric composition containing active polypeptides, pharmaceutical compositions and methods of using the same The invention is directed to compositions comprising polyvalent complexes containing a biocompatible polymer backbone to which is attached a plurality of monomeric anti-microbial peptides and to methods for using such complexes to stabilize anti-microbial peptides for treating or preventing a disease or condition resulting from infection with a microbe. Multivalent ... 03/08/07 - 20070053933 - Il28 and il29 truncated cysteine mutants and antiviral methods of using same IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof ... 03/01/07 - 20070048333 - Cd4+ t-lymphocyte-specific hepatitis c virus-epitopes The invention relates to Hepatitis C virus epitopes which are specific in relation to CD4+ T lymphocytes, in addition to vaccinations which contain said epitopes. ... 03/01/07 - 20070048332 - Stabilized liquid anti-rsv antibody formulations The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, ... 02/22/07 - 20070042000 - Porcine reproductive and respiratory syndrome vaccine based on isolate ja-142 Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of ... 02/22/07 - 20070041999 - Production of multivalent virus like particles The present invention is directed to the production and in vitro assembly of recombinant viral capsid proteins into virus like particles. In particular, the present invention provides rapid, scalable, and cost efficient methods for the production of multivalent virus like particles utilizing separate populations of capsid fusion peptides containing differing ... 02/22/07 - 20070041998 - Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses The invention relates to the use of Alum for the preparation of a drug for enhancing an antigen-specific type 1 immune response against an antigen in the presence of a type 1 inducing adjuvant. ... 02/15/07 - 20070036826 - Influenza immunogen and vaccine A chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (HBc) protein is disclosed that contains an immunogen for inducing the production of antibodies to the influenza M2 protein. An immunogenic influenza sequence in two to four copies is preferably expressed at or near the N-terminus or in the HBc immunogenic loop ... 02/15/07 - 20070036825 - Flavivirus ns5a proteins for the treatment of hiv GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving a-GBV-C NS5A peptide or polypeptide for inhibiting and treating HIV infections. ... 02/15/07 - 20070036824 - Optimized expression of hpv 58 l1 in yeast Synthetic DNA molecules encoding the HPV58 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV58 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV58 virus-like particles (VLPs), and to produce vaccines and ... 02/08/07 - 20070031452 - Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes The invention provides viral material and nucleotide fragments associated with multiple sclerosis and/or rheumatoid arthritis for use in method of diagnosis, prophylaxis, and therapy. ... 02/08/07 - 20070031451 - Inactivating pathogens with hydrogen peroxide for vaccine production The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites. The disclosure also provides vaccine compositions ... 02/08/07 - 20070031450 - Stabilizers for veterinary vaccines A formulation for a animal vaccines is provided. The vaccine formulation contains a stabilizer component and a viral immunogen. The stabilizer component includes a substantially TSE/BSE-safe animal-based protein and a vegetable-based protein. The stabilizer component provides for the stabilization of a vaccine throughout its storage and administration. ... 02/01/07 - 20070026014 - Interferon beta in severe acute respiratory syndrome (sars) The us of an interferon (IFN) for the manufacture of a medicament useful for treatment and/or prevention of Severe Acute Respiratory Syndrome (SARS) is described in the present invention. ... 01/25/07 - 20070020290 - Natural antibodieactive against hiv virus A preparation of human antibodies capable of neutralizing HIV-1 virus and the use thereof in the treatment of HIV infection. ... 01/25/07 - 20070020289 - Preparations and processes for stabilizing biological materials by means of drying processes without freezing The present invention concerns processes for the production of dry, partially amorphous products containing biologically active and in particular therapeutically active material which are macroscopically homogeneous substance mixtures, the substance mixtures being selected from at least one substance of each of the groups (i) carbohydrate or zwitterion with a polar ... 01/25/07 - 20070020288 - Vaccine This invention pertains to methods for treating infections caused by human papillomaviruses. It has been determined that immunization with HPV 16 and HPV 18 virus like particles provides cross-protection against other HPV types. ... 01/18/07 - 20070014813 - Conserved motif of hepatitis c virus e2/ns1 region The hypervariable region (E2HV) of the putative hepatitis C virus (HCV) glycoprotein E2/NS1, between about amino acid 384 to about amino acid 414, is a rapidly evolving region of HCV, and is likely to be under positive immune selection. A newly discovered motif within this hypervariable region is immunogenic and ... 01/11/07 - 20070009550 - Postweaning multisystemic wasting syndrome and porcine circovirus from pigs The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in ... 01/11/07 - 20070009549 - Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response The present invention relates to HIV-1 envelope proteins from a donor with non-progressive HIV-1 infection whose serum contains broadly cross-reactive, primary virus neutralizing antibody. The invention also relates to isolated or purified proteins and protein fragments that share certain amino acids at particular positions with the foregoing HIV-1 proteins. ... 01/04/07 - 20070003575 - Viral and viral associated mirnas and uses thereof Described herein are novel polynucleotides associated with viral infections. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of viral infections. ... 01/04/07 - 20070003574 - Picornaviruses, vaccines and diagnostic kits A new group of picornaviruses is disclosed. The picornaviruses of the invention comprise in the non-coding region of their viral genome a nucleotide sequence which corresponds to cDNA sequence (I) or homologous sequences having at least 75% homology to the SEQ ID NO:1, and they cause mammalian disease. Further aspects ... 01/04/07 - 20070003573 - Picornaviruses, vaccines and diagnostic kits A new group of picornaviruses is disclosed. The picornaviruses of the invention comprise in the non-coding region of their viral genome a nucleotide sequence which corresponds to cDNA sequence (1) or homologous sequences having at least 75% homology to the SEQ ID NO:1, and they cause mammalian disease. Further aspects ... 01/04/07 - 20070003572 - The genome of the hiv-1 inter-subtype (c/b') and use thereof The present invention refers to a polynucleotide comprising the nucleic acid sequence as depicted in SEQ ID NO:1, 2 or 3 or the fragment or derivative thereof, or a polynucleotide hybridizing with the nucleic acid sequence as depicted in SEQ ID NO:1, 2 or 3. The present invention further refers ... 01/04/07 - 20070003571 - Virus strains The present invention relates to clinical herpes simplex virus (HSV) isolates with improved oncolytic capabilities as compared to reference laboratory HSV strains. The present invention also relates to methods of producing HSV strains of the invention and to pharmaceutical compositions comprising a HSV strain of the invention. ... 01/04/07 - 20070003570 - Identifying virally infected and vaccinated organisms This document provides methods and materials related to assessing organisms for the presence or absence of anti-virus antibodies. For example, this document provides methods and materials that can be used to determine whether or not an organism (e.g., a member of a swine species such as a pig) contains anti-PRRS ... 12/28/06 - 20060292177 - Postweaning multisystemic wasting syndrome and porcine circovirus from pigs The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in ... 12/28/06 - 20060292176 - In ovo vaccine against infectious bursal disease The present invention relates to a non pathogenic vaccine comprising a recombinant Infectious Bursal Disease virus that includes a recombinant Segment A, designated as rD78GLSNSΔ, that includes sequences from D78 and GLS strains and wherein the NS protein is not expressed. ... 12/28/06 - 20060292175 - Chimeric alphavirus replicon particles Chimeric alphaviruses and alphavirus replicon particles are provided including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations ... 12/28/06 - 20060292174 - Self-assembling nanoparticle drug delivery system A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting ... 12/21/06 - 20060286123 - prrs vaccines The present invention is related to improved modified live PRRS vaccines of European genotype and new PRRSV strains which can be used for the manufacture of such vaccines. ... 12/14/06 - 20060280756 - Novel composition Novel combined vaccine compositions are provided, comprising a herpes simplex virus (HSV) antigen and a HPV antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a hepatitis B viral antigen, a VZV antigen, a HCMV antigen, Toxoplasma ... 12/14/06 - 20060280755 - Modulation of nkg2d The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D. ... 12/14/06 - 20060280754 - Method of preventing virus: cell fusion by inhibiting the function of the fusion initiation region in rna viruses having class i membrane fusogenic envelope proteins The present invention relates to a method of preventing or inhibiting viral infection of a cell and/or fusion between the envelope of a virus and the membranes of a cell targeted by the virus (thereby preventing delivery of the viral genome into the cell cytoplasm, a step required for. viral ... 12/07/06 - 20060275323 - Particles of hcv envelope proteins: use for vaccination The present invention is based on the finding that the envelope proteins of HCV induce a beneficial immune response in chronically HCV-infected chimpanzees. The immunization can preferentially be carried out using HCV envelope proteins in the form of particles which are produced in a detergent-assisted manner. The envelope proteins when ... 12/07/06 - 20060275322 - Modified hcv peptide vaccines Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139, an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2, and a fragment of an HCV ... 12/07/06 - 20060275321 - Polypeptide antagonists of hiv-1 tat protein Compositions and methods of using such compositions to regulate biological responses associated with binding of HIV-1 polypeptides. ... 11/30/06 - 20060269572 - Accelerated vaccination The present invention relates to genetic vaccines for stimulating cellular and humoral immune responses in humans and other hosts, and, in particular, relates to recombinant viruses that express heterologous antigens of pathogenic viruses, in single dose form. ... 11/23/06 - 20060263388 - Therapeutic agent for fibromyalgia A therapeutic agent for fibromyalgia containing an extract from inflamed tissue inoculated with vaccinia virus as an active ingredient, use of the extract from inflamed tissue inoculated with vaccinia virus as the active ingredient for producing a medicinal composition for treating fibromyalgia, and a method of treating fibromyalgia which comprises ... 11/23/06 - 20060263387 - Recombinant porcine adenovirus vector This invention relates to a recombinant vector including a recombinant porcine adenovirus, stably incorporating and capable of expression of at least one heterologous nucleotide sequence. The nucleotide sequence is preferably one which encodes an antigenic determinant of Hog Cholera Virus or Pseudorabies virus. The further invention relates to a method ... 11/23/06 - 20060263386 - Vaccines The invention refers to an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZXZN-XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues. ... 11/16/06 - 20060257426 - Nanoemulsion vaccines The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods and compositions for the use of nanoemulsion compounds as mucosal adjuvants to induce immunity against environmental pathogens. Accordingly, in some embodiments, the present invention provides nanoemulsion vaccines comprising a nanoemulsion and ... 11/16/06 - 20060257425 - Inactivated nodavirus vaccine A vaccine against nodavirus infection in fish can be produced by inactivating the virus using an aziridine compound. This vaccine can be used to prevent Viral Nervous Necrosis (VNN) in a variety of fish species. ... 11/16/06 - 20060257424 - Attenuated circovirus An isolated attenuated circovirus having a mutation in viral nucleic acid encoding viral protein 2 (VP2). The attenuated circovirus is particularly suitable for use in conferring immunity in an animal, particularly birds. ... 11/09/06 - 20060251681 - Methods for producing marburg virus proteins Using the MBGV GP, NP, and virion proteins, a method and composition for use in inducing an immune response which is protective against infection with MBGV in nonhuman primates is described. ... 11/09/06 - 20060251680 - Mannose immunogens for hiv-1 Methods of producing a carbohydrate HIV vaccine or immunogenic composition are provided. One method comprises expressing a glycoprotein with a modified glycosylation, which facilitates binding of the glycoprotein to the 2G12 antibody. Another method comprises iteratively selecting cells with a high affinity for the 2G12 antibody. ... 11/09/06 - 20060251679 - Ferritin fusion proteins for use in vaccines and other applications An isolated ferritin fusion protein is provided in which ferritin is fused with a protein or peptide capable of being fused to ferritin without interfering with the polymeric self-assembly of the resulting fusion protein, and the protein may be of the endocapsid form when fused at the C terminus or ... 11/09/06 - 20060251678 - Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof The present invention provides a Venezuelan equine encephalitis virus replicon RNA useful in the development of stable lines of mammalian, avian and insect cells in which these replicons will persistently replicate. Venezuelan equine encephalitis (VEE) virus replicons contain a number of unique adaptive mutations that make the replicons noncytopathic. The ... 11/09/06 - 20060251677 - Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against ... 11/09/06 - 20060251676 - Hpv-16 and-18 l1 vlp vaccine The invention relates to use of HPV 16 and HPV 18 VLPs to provide cross protection against infection and/or disease by other HPV types. ... 10/26/06 - 20060240041 - Prrsv vaccines The invention relates to the field of PRRS viruses and infectious clones obtained from PRRS viruses. Furthermore, the invention relates to vaccines and diagnostic assays obtainable by using and modifying such infectious clones of PRRS viruses. The invention provides a porcine reproductive and respiratory syndrom virus (PRRSV) replicon having at ... 10/26/06 - 20060240040 - Optimized expression of hpv 45 l1 in yeast Synthetic DNA molecules encoding the HPV45 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV45 L1 protein, wherein said polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV45 virus-like particles (VLPs), and to produce vaccines ... 10/26/06 - 20060240039 - Vaccines The present invention relates to a vaccination comprising co-administration of an antigen and viral vector providing immunity at both humoral and antibody levels. ... 10/26/06 - 20060240038 - Cells used as carriers for bacteria The invention relates to the use of a cell, which is charged with a micro-organism that contains foreign DNA, in particular a bacterial micro-organism, to produce a pharmaceutical composition. Preferably, the foreign DNA codes for a defined active agent and the pharmaceutical composition is designed for use in the prophylaxis ... 10/19/06 - 20060233831 - Novel vaccine formulations The present invention relates to oil-in-water emulsions, their use as adjuvants, and pharmaceutical, immunologic, or vaccine compositions that may comprise the same. In one embodiment, the oil-in-water (O/W) emulsion may comprise an aqueous solution containing an immunogen, a mineral oil, a non-ionic lipophilic ethoxylated fatty alcohol and a non-ionic hydrophilic ... 10/19/06 - 20060233830 - Vaccines Processes for the production of a stabilised vaccine composition of labile immunogens, wherein a fluid comprising one or more immunogens is sprayed into a reactor containing fluidised particles of a pharmaceutically acceptable water soluble material at a temperature of about 25° C. to about 50° C., such that the immunogen ... 10/12/06 - 20060228375 - Induction of mucosal immunity by vaccination via the skin route Methods for generating an immune response at a mucosal surface are described. Compositions suitable for use in the methods for generating an immune response at a mucosal surface are also described. In addition, methods for treating or preventing a disease caused by the entry of a pathogen into the body ... 10/05/06 - 20060222664 - Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production The present invention generally relates to the field of immunology and provides immunoprotective compositions and methods for preparing such compositions from transgenic plant cells. The present invention also relates to the field of protein production (e.g., the recombinant production of enzymes, toxins, cell receptors, ligands, signal transducing agents, cytokines, or ... 10/05/06 - 20060222663 - Circovirus sequences associated with piglet weight loss disease (pwd) The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors; methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, ... 10/05/06 - 20060222662 - Composition to be administered to a living being and method for marking agents The invention relates to compositions to be administered to a living being, a method for marking agents that are administered to living beings, the use thereof, and an accelerated test. ... 10/05/06 - 20060222661 - Infectious hepacivirus pseudo-particles containing functional e1, e2 envelope proteins The invention relates to the generation and the use of hepacivirus pseudo-particles containing native functional E1, E2 envelope glycoproteins assembled onto retroviral core particles. These particles are highly infectious and constitute a valid model of hepacivirus virion. ... 09/28/06 - 20060216310 - Methods of treating and detecting cancer using viruses The invention provides a method of treating cancer in a mammal comprising administering to the mammal an effective amount of virus, particularly Newcastle Disease Virus or other Paramyxovirus. The invention also provides a method of treating cancer in a mammal comprising administering such viruses to the mammal in combination with ... 09/21/06 - 20060210587 - Virus-like particles for the induction of autoantibodies The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the ... 09/07/06 - 20060198853 - Papilloma virus capsomere vaccine formulations and methods of use Vaccine formulations comprising viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed. ... 08/31/06 - 20060193873 - Functionallly reconstituted viral membranes containing adjuvant The present invention relates to vaccines directed against antigens such as membrane proteins from pathogens or tumor cells. The invention further relates to methods of forming reconstituted viral membranes, with membrane fusion activity, which are lipid bilayer membranes preferably containing natural lipids of a virus, a viral fusion protein, one ... 08/24/06 - 20060188522 - Viral agents A viral DNA construct, and virus encoded thereby, is provided having one or more tumour specific transcription factor binding sites in place of one or more wild type transcription factor binding sites operatively positioned in the promoter region which controls expression of early genes responsible for viral nucleic acid replication. ... 08/24/06 - 20060188521 - Treatment of t cell disorders The present invention relates to a method for treating a T cell disorder in a subject involving disrupting sex steroid signaling to the thymus and introducing into the subject bone marrow or haemopoietic stem cells (HSC). ... 08/24/06 - 20060188520 - Protective antigen of epstein barr virus The present invention relates to the identification of a subunit vaccine to prevent or treat infection of Epstein Barr Virus. In particular, EBNA-1 was identified as a vaccine antigen. In a specific embodiment, a purified protein corresponding to EBNA-1 elicited a strong CD4+ T cell response. The responsive CD4+ T ... 08/24/06 - 20060188519 - Peptides, antibodies, and methods for the diagnosis of sars The present invention discloses 27 immunoreactive peptides and antibodies immunologically reactive with said peptides. Such peptides and antibodies can be used for diagnosis of SARS-CoV infection as well as for preparing vaccination against SARS-CoV or a closely related coronaviruses. ... 08/17/06 - 20060182764 - Vaccines containing ribavirin and methods of use thereof The present invention relates to compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans. More particularly, the use of Ribavirin as an adjuvant to a vaccine protocol and compositions having Ribavirin and an antigen are described. ... 08/17/06 - 20060182763 - Cd8 t cell epitopes in hpv 16 e6 and e7 proteins and uses thereof The present invention is directed to the examination of the pattern of immunodominant CD8 T cell epitopes in the E6 and E7 protein of Human Papillomavirus (HPV) and its further characterization in terms of its amino acid sequence and HLA restriction. These epitopes are identified based on their ability to ... 08/17/06 - 20060182762 - enterovirus, vaccines, medicaments and diagnostic kits The invention provides a new enteroviral species call EV79, and functional parts, derivatives and analogues of said virus. Proteinaceous molecules capable of specifically binding EV79, such as isolated or recombinant antibodies, are also herewith provided. A virus and/or proteinaceous molecule of the invention is particularly suitable for diagnosis of an ... 07/13/06 - 20060153870 - Method for the recovery of non-segmented, nagative-stranded rna viruses from cdna Methods for producing infectious, non-segmented, negative-stranded RNA viruses of the Order Mononegavirales are provided that involve coexpression of a viral cDNA along with essential viral proteins, N, P, and L in a host cell transiently transfected with an expression vector encoding an RNA polymerase. In alternate methods, after the host ... 07/06/06 - 20060147468 - Inactivated influenza virus vaccine for nasal or oral application The invention relates to nasal or oral administration of a compound containing inactivated influenza virus antigen and aluminum as adjuvant for the prophylaxis of influenza virus infections. Said vaccine is especially suitable for inducing a mucosal IgA immune response and systemic IgG immune response. ... 07/06/06 - 20060147467 - Materials and methods for immunizing against fiv infection The subject invention pertains to methods and compositions for protecting feline animals from infection by FIV using immunogens derived from primate immunodeficiency viruses, including HIV and SIV. Methods for vaccinating feline animals with the subject vaccine compositions are described. Feline animals vaccinated according to the methods and compositions of the ... 06/29/06 - 20060140977 - Methods for assaying inhibition of hiv-1 envelope glycoprotein-mediated membrane fusion This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell, but not a T cell-tropic isolate of HIV-1 to a CD4+ cell; and agents determined to be capable of specifically inhibiting the fusion of a T ... 06/22/06 - 20060134137 - Transduction vector based on modified hiv-2 A lentiviral vector system for gene transfer and gene therapy is disclosed. The system is based on human immunodeficiency virus type 2 (HIV-2), and uses a split-genome approach. The vector system can integrate into a host genome regardless of cell division. It may be used in terminally-differentiated cells. It has ... 06/01/06 - 20060115495 - Protein-noble metal nanoparticles The present invention is a composition and method of making protein-noble metal nanoparticles and methods for using the same as anti-virals. ... 05/25/06 - 20060110405 - Plasma or serum fraction for treatment and prevention of viral infections and related conditions The present invention describes compositions and methods for the treatment and/or prevention of viral infections and related conditions, including HIV infections. ... 05/25/06 - 20060110404 - Set of ubiquitous cellular proteins involved in viral life cycle A method of modulating viral RNA replication and translation, in a eukaryotic cell, of positive-strand viral RNA, comprising the step of contacting a viral RNA-binding protein (vRbp) with a compound that modulates an activity of said protein. ... 05/25/06 - 20060110403 - Non-human herpesviruses as vectors The present invention relates to animal viruses such as animal herpesviruses as a vector for diagnostic, therapeutic and prophylactic delivery of foreign genes and nucleic acids to animals, human or primary cells derived thereof, respectively. By using said viruses, the prevention and treatment of infectious, autoimmune and tumor diseases as ... 05/18/06 - 20060104992 - Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising this fragment for detecting, preventing, and treating hiv The inventions provide an isolated antiviral peptide characterized by the amino acid sequence GDEPLENYLDTEYF (SEQ ID:NO 1) and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41 and human CD4 cells. It has postulated anti-retroviral activity in vivo, particularly anti-HIV-1 activity. The inventions further provide pharmaceutical ... 04/27/06 - 20060088551 - Functional fragments of hiv-1 vpr protein and methods of using the same Conjugated compositions comprising a fragment of HIV-1 Vpr or a non-HIV-1 Vpr protein conjugated to a therapeutic compounds and methods of using the same to deliver therapeutic compounds to a cell's nucleus or for the preparation of drug delivery particles are disclosed. Functional fragments of HIV-1 Vpr and functional non-HIV-1 ... 04/20/06 - 20060083756 - Circovirus sequences associated with piglet weight loss disease (pwd) The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a ... 04/20/06 - 20060083755 - Vaccine for feline infectious peritonitis FIP vaccines were provided that use an N protein with a specific structure, or a fragment thereof, as an antigen. Preferred antigens of this invention are N proteins derived from a specific type I virus strain (KU-2). Vaccines comprising such an N protein confer preventive effects against a wide range ... 04/06/06 - 20060073166 - Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders The present invention pertains to methods for preventing reovirus recognition in the treatment of cellular proliferative disorders, and particularly ras-mediated cellular proliferative disorders, in mammals. The mammal may be selected from dogs, cats, sheep, goats, cattle, horses, pigs, mice, humans and non-human primates. The method comprises suppressing or otherwise inhibiting ... 04/06/06 - 20060073165 - Vaccine against infectious agents having an intracellular phase, composition for the treatment and prevention of hiv infections, antibodies and method of diagnosis A vaccine for treating and/or preventing infectious diseases where the infectious agent has at least one intracellular phase in the host during its multiplication cycle is disclosed. The vaccine comprises at least one cryptic epitope of a cellular element that is carried along by an intracellular infectious agent as it ... 04/06/06 - 20060073164 - Dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) ... 03/23/06 - 20060062806 - Flavivirus variants having phenotypic variation and immunogenic compositions thereof The present invention concerns isolated attenuated flaviviruses, such as West Nile viruses, having modifications that provide phenotypic varation, particularly in comparison to a more virulent reference strains. The invention encompasses the isolated viruses and immunogenic compositions thereof, in addition to methods to produce and utilize same. ... 03/23/06 - 20060062805 - Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (prrsv) The present invention provides an isolated DNA sequence encoding, for example, at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORF's) of an Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), specifically ISU-12, and the polypeptides encoded by ... 03/23/06 - 20060062804 - Sars-cov-specific b-cell epitope and applications thereof Disclosed is SARS-CoV-specific B-cell epitope and applications thereof. The epitopes are peptides and can either be expressed in phages or synthesized to diagnose SARS patients accurately. High sensitivity and specificity of the serologic detection are achievable by using a plurality of SARS-CoV-specific B-cell epitope-based peptides. Therefore, the peptides can be ... 03/16/06 - 20060057162 - Induction of cytotoxic t-lymphocyte responses Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing a microfluidized antigen formulation which comprises, consists, or consists essentially of ... 03/16/06 - 20060057161 - Detection of coronavirus infection Isolated polypeptides containing one of SEQ ID NOs: 1-11. Also disclosed are (i) isolated nucleic acids encoding the polypeptides and related expression vectors and host cells; (ii) purified antibodies that recognize the polypeptides; and (iii) methods of producing the polypeptides, diagnosing infection with a coronavirus, and producing the antibodies. ... 03/09/06 - 20060051374 - Compositions and methods for mucosal vaccination The present invention provides pharmaceutical combinations that include an IRM compound formulated for mucosal administration and an antigen formulated for mucosal administration. Additionally, the invention provides methods for immunizing a subject. Generally, the methods include administering an antigen to a mucosal surface of the subject in an amount effective, in ... 03/09/06 - 20060051373 - Particle-bound human immunodeficiency virus envelope glycoproteins and related compositions and methods This invention provides a first composition comprising a pharmaceutically acceptable particle and a stable HIV-1 pre-fusion envelope glycoprotein trimeric complex operably affixed thereto. This invention further provides a second composition comprising (a) a pharmaceutically acceptable particle, (b) an antigen, and (c) an agent which is operably affixed to the particle ... 02/16/06 - 20060034868 - Methods and vaccines for providing in ovo protection against turkey rhinotracheitis Methods and compositions for protecting avian hosts (e.g., turkeys and/or chickens) from turkey rhinotracheitis virus and/or TRT or SHS respiratory distress utilize in ovo administration of live, avirulent strains of TRTV at appropriate dosage levels on a per egg basis to provide an effective and efficient vaccination having acceptable safety ... 01/26/06 - 20060018926 - Noscapine derivatives as adjuvant compositions and methods of use thereof An adjuvant composition comprising noscapine and its derivatives, for use in the treatment of tumors, cancer, as an adjuvant for vaccines. ... 01/26/06 - 20060018925 - Compositions and methods for modulating rsv infection and immunity Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The ... 01/19/06 - 20060013831 - Composition and method for enhancing immune response A composition and method for enhancing immune response in a living organism is disclosed. In particular, the present disclosure provides an adjuvant peptide for use in raising an immune response to an antigen. The adjuvant peptide is selected from a group of peptides with an HIV-related sequence. Additionally, the adjuvant ... 01/12/06 - 20060008473 - Influenza hemagglutinin and neuraminidase variants Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided. ... 01/12/06 - 20060008472 - Antigen delivery compositions and methods of use The present invention provides antigen delivery compositions and methods of using same to prevent or to treat cancers and other infectious diseases. More particularly, the present invention provides a lipid-protamine-DNA (LPD) vaccine delivery system and methods of using such LPD vaccine delivery system for the prevention and treatment of cancer ... 12/29/05 - 20050287172 - Influenza hemagglutinin and neuraminidase variants Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided. ... 12/29/05 - 20050287171 - Vaccine comprising an attenuated pestivirus Attenuated pestiviruses, in particular attenuated BVDV, wherein at least one mutation is in the coding sequence for glycoprotein Erns and at least another mutation in the coding sequence for Npro which preferably leads to combined inactivation of the RNase activity residing in glycoprotein Erns in addition to the inactivation of ... 12/29/05 - 20050287170 - Subunit vaccine against west nile viral infection An immunogenic composition is described that preferably contains a recombinantly produced form of truncated West Nile envelope glycoprotein and one or more adjuvants acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent populations. The disclosed immunogenic compositions can further comprise a recombinantly produced non-structural (non-envelope) West Nile ... 12/22/05 - 20050281845 - Hapten-carrier conjugates and uses thereof The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as ... 12/22/05 - 20050281844 - Immunization for ebola virus infection Ebola virus vaccines comprising nucleic acid molecules encoding Ebola viral proteins are provided. In one embodiment, the nucleic acid molecule encodes the transmembrane form of the viral glycoprotein (GP). In another embodiment, the nucleic acid molecule encodes the secreted form of the viral glycoprotein (sGP). In yet another embodiment, the ... 12/08/05 - 20050271685 - Cellular permissivity factor for viruses and uses thereof The present invention provides methods and compositions related to the generation of host cells permissive for virus growth, particularly Porcine Reproductive and Respiratory Syndrome (PRRS) virus. ... 12/08/05 - 20050271684 - Apparatus and method for transdermal delivery of multiple vaccines An apparatus and method for transdermally delivering an immunologically active agent comprising a delivery system having a microprojection array that includes a plurality of microprojections that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers, the microprojection array having a plurality ... 12/01/05 - 20050266023 - Generation of virus-like particles and use as panfilovirus vaccine In this application are described filovirus-like particles for both Ebola and Marburg and their use as a diagnostic and therapeutic agent as well as a filovirus vaccine. Also described is the association of Ebola and Marburg with lipid rafts during assembly and budding, and the requirement of functional rafts for ... 12/01/05 - 20050266022 - Methods and compositions for use in the treatment of filovirus mediated disease conditions Methods and compositions are provided for at least slowing the progression of a filovirus mediated disease condition in a host. In the subject methods, an effective amount of an agent that at least reduces the amount of folate receptor mediated filovirus cell entry is administered to the host. The subject ... 12/01/05 - 20050266021 - Powder compositions A gel-forming free-flowing powder suitable for use as a vaccine is prepared by spray-drying or spray freeze-drying an aqueous suspension that contains an antigen adsorbed to an aluminum salt or calcium salt adjuvant, a saccharide, an amino acid or a salt thereof, and a colloidal substance. Powder for vaccine purposes ... 11/24/05 - 20050260228 - Vaccines absorbable by the transmucosal way The main object of the present invention is to provide polysaccharide-coated antigens derivatised with lectins for pharmaceutical use. In said vaccines, polysaccharides are preferably selected from the group consisting of chitosan, low-molecular-weight and high-deacetylation-degree chitosan, methyl glycol. chitosan, alginic acid, polymannuronic acid and salts or derivatives thereof. In the vaccines ... 11/24/05 - 20050260227 - Novel therapeutic processes for treating cancer with specific antigens This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination ... 11/24/05 - 20050260226 - Novel therapeutic processes for treating infectious agents by training or adoptive transfer of immune cells, and useful compositions therefor This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination ... 11/10/05 - 20050249754 - Cd4+ t-lymphocyte-specific hepatitis c virus epitopes The invention relates to hepatitis C virus epitopes which are CD4+ T-lymphocyte specific, and to vaccines containing these epitopes. ... 11/10/05 - 20050249753 - Variable region of the monoclonal antibody against the hbv s-surface antigen and a gene encoding the same The present invention relates to a variable region of the monoclonal antibody against the S-surface antigen of hepatis B virus and a gene encoding the same, a recombinant vector containing the said gene, and a transformant obtained from the said recombinant vector. ... 11/03/05 - 20050244433 - Treatment of papillomavirus infections This invention relates to treatment of papillomavirus infections. Primarily there is provided a method of treatment of an existing papillomavirus (PV) infection which includes the step of administration of PV VLPs selected from the group consisting of PV L1 VLPs and PV L1/L2 VLPs to a patient suffering from the ... 11/03/05 - 20050244432 - Vaccine The present invention relates to mixed VLPs, and to a process for the production of a mixed VLP, the VLPs comprising L1 proteins from at least 2 different types of human papillomavirus. ... 10/27/05 - 20050238662 - Circovirus sequences associated with piglet weight loss disease (pwd) The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a ... 10/27/05 - 20050238661 - Infectious cdna clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof Infectious cDNA clones of North American Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) are provided. Further provided are cDNA clones comprising genetic mutations. Also provided are vaccines comprising cDNAs, including genetically and immunologically marked vaccines for North American PRRSV. ... 10/27/05 - 20050238660 - Cpg formulations and related methods The invention involves methods and compositions of an immunostimulatory nucleic acid in combination with other therapeutic formulations such as oil-in-water emulsions. The combination of therapeutics are administered in various dosages or at various time schedules for the treatment of disorders such as disease and cancer. ... 10/20/05 - 20050232949 - Vaccines expressed in plants The anti-viral vaccine of the present invention is produced in transgenic plants and then administered through standard vaccine introduction method or through the consumption of the edible portion of those plants. A DNA sequence encoding for the expression of a surface antigen of a viral pathogen is isolated and ligated ... 10/13/05 - 20050226893 - Lyophilization method to improve excipient crystallization The present invention provides improved methods to lyophilize (freeze-dry) active ingredients such as proteins, nucleic acids and viruses. The present methods improve the degree of excipient crystallization during lyophilization over prior methods. The improvement in excipient crystallization is based, in part, on a high-temperature annealing step is conducted prior to ... 10/06/05 - 20050220815 - Method of measuring the duration of adequate immune memory in companion animals Methods to measure the duration of adequate immune memory for animal vaccines involving a retrospective analysis utilizing veterinary vaccine administration histories and clinical histories, and markers of immunity of animals in the field to derive a vaccine's duration of adequate immune memory. ... 10/06/05 - 20050220814 - Microfluidized oil-in-water emulsions and vaccine compositions This invention provides submicron oil-in-water emulsions useful as a vaccine adjuvant for enhancing the immunogenicity of antigens. The present invention also provides vaccine compositions containing an antigen combined with such emulsions intrinsically or extrinsically. Methods of preparing the emulsions and vaccines are also provided by the present invention. ... 10/06/05 - 20050220813 - Non-spreading pestivirus The invention relates to vaccines used in the eradication or control of pestivirus infections, particularly those used in pigs or ruminants. The invention provides nucleic acid, pestivirus-like particles and a pestivirus vaccine, comprising the nucleic acid or particles, which is capable of eliciting a proper immune response without having the ... 10/06/05 - 20050220812 - Screening process A method for identifying a vaccine candidate, said method comprising selecting a protein from the proteome of a target organism on the basis of a property selected from a biophysical property or the amino acid composition of that protein. For example, using this method a first set of data for ... 09/22/05 - 20050208071 - Replicons of pestviruses that do not express c and or e1 protein and infectious viral patricles containing same, that can be used in vaccines The present invention provides new Pestiviral RNA genomes (replicons) that are able to replicate, and can be packaged into infectious viral particles in cells that complement the missing protein(s), but do not produce infectious progeny virus. Such replicons can be useful for vaccine purposes. The replicons encode most, preferably all, ... 09/01/05 - 20050191319 - Microparticles with adsorbent surfaces, methods of making same, and uses thereof Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the ... 08/25/05 - 20050186222 - Vaccines against west nile virus The present invention relates to novel vaccines containing (whole-inactivated) West Nile Viruses and/or West Nile viral proteins derived therefrom, produced on human cells, wherein the human cells comprise a sequence encoding at least one early region-1 (E1) gene product of an adenovirus. The cells are preferably cultured in suspension to ... 08/25/05 - 20050186221 - Vaccine stabilizer method A method of treating livestock with a vaccine includes mixing a reducing agent, such as sodium thiosulfate, with water, which may include oxidizing water sanitizers, mixing the vaccine with the water after the reducing agent has neutralized the water sanitizers, and treating the livestock with the vaccine and water mixture. ... 08/25/05 - 20050186220 - T helper cell epitopes The present invention provides T helper cell epitopes and compositions for use in inducing an immune response comprising at least one of these epitopes. The epitopes are contained within a peptide sequence selected from the group consisting of PRTSDRPVSYTMNRTRS (SEQ ID NO: 4); TRSRKQTSHRLKNIPVH (SEQ ID NO: 5); SHQYLVIKLIPNASLIE (SEQ ... 08/18/05 - 20050180993 - Assays for assembly of ebola virus nucleocapsids The present invention relates to assays for the identification of compounds that inhibit assembly of NP, VP35, and VP24, or inhibit the glycosylation of NP, required for nucleocapsid formation, for use as anti-viral agents. The invention also relates to assays for the identification of compounds that block glycosylation of proteins ... 08/18/05 - 20050180992 - Viral fibers Long rod shaped M13 viruses were used to fabricate one dimensional (1D) micro- and nanosized diameter fibers by mimic the spinning process of the silk spider. Liquid crystalline virus suspensions were extruded through the micrometer diameter capillary tubes in cross-linking solution (glutaraldehyde). Resulting fibers were tens of micrometers in diameter ... 08/11/05 - 20050175634 - Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction The pharmaceutical composition is useful for treating epithelial tumors in a subject and contains at least two antigens and a pharmaceutically acceptable carrier, where each of the antigens induces or is capable of inducing a cutaneous delayed type hypersensitivity (DTH) response in the subject. This composition is particularly useful in ... 08/11/05 - 20050175633 - Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (prrsv), proteins encoded by the polynucleic acids, vaccines based on the proteins and/or polynucleic acids, a method of protecting a pig from a prrsv and a method of de The present invention provides a purified preparation containing a polynucleic acid encoding at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORF's) of an Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), proteins at least 80% but less ... 08/11/05 - 20050175632 - Viral antigens The present invention relates to a vaccine composition comprising VLPs containing L1 proteins or functional L1 protein derivatives from HPV 16, HPV 18, HPV 31 and HPV 45 genotypes. ... 08/11/05 - 20050175631 - Hiv vaccine and method of use This invention is directed to pharmaceutical compositions comprising an HIV antigen and a mucosal adjuvant and methods for raising an immune response in a subject by administering these compositions. Preferably, the pharmaceutical compositions of the invention can be used to treat or prevent HIV infection. ... 08/04/05 - 20050169938 - Plant lectins as mucosal adjuvants The invention provides a method of increasing an immune response in a mammal. The method involves administering to the mammal an admixture comprising an immunogen and a plant lectin. The plant lectin acts as an adjuvant to increase an immune response against the immunogen. The method is especially well-suited for ... 07/28/05 - 20050163803 - Non-animal origin stabilizers and processes for producing the same Embodiments of the present invention generally comprise stabilizers for biological products that are free from animal origin excipients/components, such stabilizers functioning well in lyophilization procedures. ... 07/21/05 - 20050158340 - Recombinant rsv virus expression systems and vaccines The present invention relates to genetically engineered recombinant RS viruses and viral vectors which contain heterologous genes which for the use as vaccines. In accordance with the present invention, the recombinant RS viral vectors and viruses are engineered to contain heterologous genes, including genes of other viruses, pathogens, cellular genes, ... 06/23/05 - 20050136073 - Use of microparticles combined with submicron oil-in-water emulsions Compositions are provided which include biodegradable microparticles with entrapped or adsorbed antigens, in combination with submicron oil-in-water emulsions. Also provided are methods of immunization which comprise administering to a vertebrate subject (a) a submicron oil-in-water emulsion, and (b) a therapeutically effective amount of a selected antigen entrapped in a microparticle. ... 06/09/05 - 20050123563 - Lipoparticles comprising proteins, methods of making, and using the same The present invention relates to lipoparticles. The invention also relates to producing lipoparticles. The invention further relates to lipoparticles comprising a viral structural protein. The invention further relates to a lipoparticle comprising a membrane protein, and the lipoparticle can be attached to a sensor surface. The invention further relates to ... 06/02/05 - 20050118196 - Novel therapeutic processes for establishing or enhancing an immunized state, and compositions useful therefor This invention provides novel processes for therapeutic applications, including the treatment of subjects carrying infectious agents or having impaired autoimmunity or impaired immune condition. The therapeutic applications disclosed herein are also directed at the treatment of cancerous subjects with malignant tumors containing cancerous cells or malignant or cancerous cells. Vaccination ... 06/02/05 - 20050118195 - Virus causing respiratory tract illness in susceptible mammals The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single stranded RNA virus (MPV) within the sub-family Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus and components thereof. ... ### FreshPatents.com Support |